In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...
MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...
Please provide your email address to receive an email when new articles are posted on . Hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors therapy can be effectively managed.
An oral potassium binder taken daily can enable the safe use of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure with reduced ejection fraction (HFrEF) who are at risk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback